Form 8-K - Current report:
SEC Accession No. 0001213900-26-065294
Filing Date
2026-06-04
Accepted
2026-06-04 16:15:32
Documents
11
Period of Report
2026-06-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0293648-8k_oruka.htm   iXBRL 8-K 31389
  Complete submission text file 0001213900-26-065294.txt   196552

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE orka-20260602.xsd EX-101.SCH 3011
3 XBRL LABEL FILE orka-20260602_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE orka-20260602_pre.xml EX-101.PRE 22356
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0293648-8k_oruka_htm.xml XML 3206
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 261065172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)